No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ASND240517P100000
- 3.30
- +0.20+6.45%
15min DelayTrading May 14 11:44 ET
3.30High3.15Low
3.15Open3.10Pre Close9 Volume429 Open Interest100.00Strike Price2.96KTurnover294.61%IV-25.23%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry3.30Time Value100Contract SizeAmericanOptions Type-0.1468Delta0.0062Gamma40.13Leverage Ratio-1.2410Theta-0.0020Rho-5.89Eff Leverage0.0291Vega
Intraday
- 5D
- 1D
News
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism wi
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.63% on an annualized basis producing an average annual return of 28.88%. Currently, Ascendis Pharma has a market
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Comments
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
7
2
Ascendis Pharma's high share price may risk investor returns as future revenue forecasts are less promising. While most investors are hopeful for a business turnaround, analysts are less confident.
1
Despite strong revenue growth, the stock's fall in price can be viewed negatively, possibly due to overly optimistic growth projections. The stock's current dip might offer a good entry point if it continues displaying signs of sustainable long-term growth.
QUICK SCALP 84 $ASND — STOCK & OPTION PLAY
ALERT ON: $84.00
ON THE WATCH: $84.11
🥇 SIGNED OF MORE UPTREND: $84.25
NEED IT TO BREAK OVER: $84.49
key indicator for MORE uptrend $84.69
confirmation uptrend - $84.72
mini breakout - $84.86
Next level of breakout: $84.98. $Ascendis Pharma A/S(ASND.US$
ALERT ON: $84.00
ON THE WATCH: $84.11
🥇 SIGNED OF MORE UPTREND: $84.25
NEED IT TO BREAK OVER: $84.49
key indicator for MORE uptrend $84.69
confirmation uptrend - $84.72
mini breakout - $84.86
Next level of breakout: $84.98. $Ascendis Pharma A/S(ASND.US$
1
QUICK SCALP 83 $ASND — STOCK & OPTION PLAY
ALERT ON: $83.09
ON THE WATCH: $83.16
🥇 SIGNED OF MORE UPTREND: $83.23
NEED IT TO BREAK OVER: $83.46
key indicator for MORE uptrend $83.59
confirmation uptrend - $83.68
mini breakout - $83.75
Prepare for a bigger breakout: $83.91 $Ascendis Pharma A/S(ASND.US$
ALERT ON: $83.09
ON THE WATCH: $83.16
🥇 SIGNED OF MORE UPTREND: $83.23
NEED IT TO BREAK OVER: $83.46
key indicator for MORE uptrend $83.59
confirmation uptrend - $83.68
mini breakout - $83.75
Prepare for a bigger breakout: $83.91 $Ascendis Pharma A/S(ASND.US$
Read more
baqklin : thanks
74349332 : what site do you get this informatiom from?